```html

Mucosal Melanoma – A Comprehensive Patient Guide

Overview

Mucosal melanoma is a rare and aggressive form of melanoma that arises from melanocytes (pigment‑producing cells) located in the mucous membranes lining body passages such as the nose, sinuses, mouth, gastrointestinal (GI) tract, vagina, and anus. Unlike the more common cutaneous (skin) melanoma, mucosal melanoma is not strongly associated with ultraviolet (UV) radiation.

• Who it affects: It can occur at any age but is most commonly diagnosed in adults aged 50‑70 years. Both sexes are affected, although certain sites show a gender predilection (e.g., vaginal melanoma is more common in women).
• Prevalence: Mucosal melanoma accounts for ≈ 1%‑2% of all melanomas worldwide. In the United States, an estimated 5,000–6,000 new cases of mucosal melanoma are diagnosed each year out of ~106,000 total melanoma cases (≈5%).<sup>1</sup>
• Prognosis: Because it is often diagnosed at an advanced stage, 5‑year survival rates range from 20% to 40%, markedly lower than cutaneous melanoma (≈92%).<sup>2</sup>

Symptoms

The signs of mucosal melanoma depend on the anatomic site. Below is a symptom checklist for the most common locations.

Nasal cavity & paranasal sinuses

• Persistent nasal congestion or obstruction
• Unexplained nosebleeds (epistaxis)
• Dark or pigmented discharge
• Facial pain or pressure
• Loss of sense of smell (anosmia)

Oral cavity & oropharynx

• Black, brown, or blue patch on the gums, palate, or tongue
• Ulcer that does not heal
• Bleeding or swelling of gums
• Persistent sore throat, hoarseness, or difficulty swallowing

Upper GI tract (esophagus, stomach)

• Difficulty swallowing (dysphagia)
• Unexplained weight loss
• Upper abdominal pain or fullness
• Occasional vomiting of blood (hematemesis)
• Chronic anemia symptoms (fatigue, pale skin)

Lower GI tract (rectum, anus)

• Rectal bleeding or dark stools
• Anal pain or itching
• Change in bowel habits (diarrhea or constipation)
• Visible pigmented lesion around the anus

Female genital tract (vagina, cervix)

• Vaginal bleeding outside of menstrual periods
• Spotting after intercourse
• Pelvic pain or pressure
• Noticeable dark lesion on the vaginal walls or cervix during exam

General systemic signs (any site)

• Unexplained fatigue
• Persistent night sweats
• Unintentional weight loss
• Lymph node swelling near the primary tumor

Causes and Risk Factors

While the exact cause of mucosal melanoma remains unclear, several factors appear to increase risk.

Genetic mutations

• c-KIT mutations – found in ~15‑30% of mucosal melanomas; these drive cell growth.
• NRAS and SF3B1 alterations – less common but implicated in tumor biology.<sup>3</sup>

Familial predisposition

• Rare inherited syndromes (e.g., Familial atypical multiple mole melanoma (FAMMM) syndrome) increase overall melanoma risk, including mucosal sites.

Environmental & lifestyle factors

• Unlike cutaneous melanoma, chronic UV exposure is not a major factor.
• Exposure to certain chemicals (e.g., formaldehyde, petroleum products) has been hypothesized but lacks strong evidence.

Other risk modifiers

• Age & sex: Incidence rises after age 50; some sites show gender tendencies (e.g., vaginal melanoma only in women).
• Immunosuppression: Organ‑transplant recipients and patients with HIV have a modestly increased risk of mucosal melanomas.
• Chronic inflammation: Long‑standing inflammatory conditions of the nasal sinuses or gastrointestinal tract may create a micro‑environment conducive to malignant transformation, though data are limited.

Diagnosis

Because mucosal melanomas often present with nonspecific symptoms, a high index of suspicion is essential.

Initial clinical evaluation

• Comprehensive history and physical examination, focusing on the relevant mucosal site.
• Endoscopic visual inspection (nasal endoscopy, laryngoscopy, colonoscopy, cystoscopy, or gynecologic exam) to locate the lesion.

Biopsy and pathology

• Incisional or excisional biopsy is the gold standard. Tissue is examined with hematoxylin‑eosin staining and immunohistochemistry (S-100, HMB‑45, Melan‑A).
• Genetic testing for c‑KIT, NRAS, and BRAF mutations guides targeted therapy.

Imaging studies

• Magnetic Resonance Imaging (MRI): Preferred for head & neck lesions to assess soft‑tissue invasion.
• Computed Tomography (CT): Useful for thoracic, abdominal, and pelvic staging.
• Positron Emission Tomography (PET)/CT: Detects distant metastases and helps with whole‑body staging.
• Ultrasound: May evaluate regional lymph nodes (e.g., cervical or inguinal nodes).

Staging

Mucosal melanoma is staged using the AJCC (American Joint Committee on Cancer) system for mucosal sites, which incorporates tumor size (T), nodal involvement (N), and distant metastasis (M). Accurate staging is crucial for treatment planning.

Treatment Options

Therapy is multimodal and tailored to tumor location, stage, and the patient’s overall health.

Surgery

• Goal: Achieve negative margins (R0 resection) while preserving organ function.
• Techniques range from endoscopic laser resection (nasal cavity) to more radical procedures (e.g., total maxillectomy, abdominoperineal resection for rectal disease).
• Sentinel lymph node biopsy is considered for head‑and‑neck and anorectal melanomas.

Radiation therapy

• Adjuvant radiotherapy improves local control, especially when surgical margins are close.
• Intensity‑modulated radiation therapy (IMRT) or proton therapy can spare surrounding critical structures.

Systemic therapies

• Immunotherapy: Checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) have shown response rates of 20‑30% in mucosal melanoma, though slightly lower than cutaneous disease.<sup>4</sup>
• Targeted therapy: For tumors harboring c‑KIT mutations, imatinib or nilotinib may be effective.
• Chemotherapy: Historically used (e.g., dacarbazine, temozolomide) but now largely replaced by immunotherapy or targeted agents.

Clinical trials

Participation in trials investigating newer agents (e.g., combination checkpoint inhibitors, oncolytic viruses, adoptive T‑cell therapy) is encouraged, especially for advanced disease.

Lifestyle & supportive measures

• Smoking cessation (particularly for oral or laryngeal lesions) enhances treatment tolerance.
• Nutritional counseling to maintain weight during therapy.
• Pain management and physical therapy for functional preservation after surgery.

Living with Mucosal Melanoma

Long‑term management focuses on surveillance, symptom control, and quality of life.

Follow‑up schedule

• First 2 years: Physical exam and imaging every 3–4 months.
• Years 3‑5: Every 6 months.
• After 5 years: Annually, or as directed by the oncologist.

Self‑monitoring tips

• Perform a weekly visual and tactile check of the primary site (e.g., nasal rinse, oral inspection with a mirror).
• Track any new bleeding, pain, or changes in lesion appearance and report promptly.
• Maintain a symptom diary—especially for fatigue, weight loss, or new neurologic signs.

Psychosocial support

• Consider counseling or support groups (e.g., Melanoma Research Foundation, Cancer Support Community).
• Address anxiety about recurrence; mindfulness, CBT, and exercise have proven benefit.
• Financial navigation services can help with insurance coverage for high‑cost immunotherapies.

Rehabilitation

• Speech therapy after head‑and‑neck surgery.
• Pelvic floor therapy for anorectal procedures.
• Dental and oral care to prevent infections after oral cavity resections.

Prevention

Because UV exposure is not a primary driver, prevention focuses on early detection and risk reduction.

• Regular medical examinations: Annual ENT or dental check‑ups that include visual inspection of mucosal surfaces.
• Prompt evaluation of persistent symptoms: Nasal bleeding, oral ulcers, or unexplained GI bleeding should be investigated without delay.
• Healthy lifestyle: Balanced diet rich in antioxidants, regular exercise, and avoidance of tobacco and excessive alcohol.
• Genetic counseling: For individuals with a strong family history of melanoma, testing for inherited mutations (e.g., CDKN2A) may be appropriate.

Complications

If left untreated or if disease progresses, several serious complications can develop.

• Local invasion: Tumor can erode bone, cartilage, or surrounding organs, leading to chronic pain, obstruction, or loss of function (e.g., nasal obstruction, dysphagia).
• Regional lymph node metastasis: Swollen, painful nodes may become infected.
• Distant metastasis: Common sites include lungs, liver, brain, and bone. Metastatic disease often presents with respiratory symptoms, neurologic deficits, or skeletal pain.
• Bleeding: Highly vascular mucosal lesions can cause recurrent or massive hemorrhage, potentially requiring transfusion.
• Secondary infections: Ulcerated lesions are entry points for bacteria, especially in the oral cavity or GI tract.
• Psychological impact: Chronic illness and functional loss can lead to depression, anxiety, and social isolation.

When to Seek Emergency Care

---

Sources:

1. Centers for Disease Control and Prevention. Melanoma Statistics. Accessed March 2024.
2. American Cancer Society. Melanoma Survival Rates. Updated 2023.
3. J.A. Busam et al., “Mucosal Melanoma: Clinical and Molecular Overview,” Journal of Clinical Oncology, 2022.
4. National Comprehensive Cancer Network (NCCN). NCCN Guidelines® for Melanoma, Version 3.2024.
5. Mayo Clinic. Mucosal Melanoma. Reviewed 2024.

```